In this interview from AAO 2022, Dr. Prithvi Mruthyunjaya provides a summary of the ocular oncology section from Retina Subspecialty Day 2022. Dr. Mruthyunjaya first discusses liquid biopsy for uveal melanoma, a real-time, minimally invasive method to detect and monitor disease progression and treatment response. He also shares an update on tebentafusp, a recently approved immunotherapeutic molecule that is the first such treatment to improve survival rates in metastatic melanoma.

Relevant financial disclosures: None.